摘要
宫颈癌患者病死率位居女性恶性肿瘤前列,严重威胁女性的生命健康。近年来,得益于靶向治疗和免疫治疗研究的发展,尤其是抗血管生成药物贝伐单抗的使用,宫颈癌患者的生存时间得到了显著延长,然而仍有部分患者疗效不佳。肿瘤分子分型从分子层面对宫颈癌进行亚型划分,可进一步区分靶向治疗及免疫治疗适应人群,有望提升临床治疗效果。现针对宫颈癌靶向治疗及免疫治疗的基础研究、临床试验及其分子分型最新进展进行系统综述。
Cervical cancer remains the leading cause of cancer-related mortality worldwide and represents a major global health challenge.Recently,the overall survival of cervical cancer patients has been significantly prolonged with the development of targeted therapy and immunotherapy,especially with the application of the anti-angiogenic drug,bevacizumab.Nevertheless,a small subset of these patients showed a poor response to targeted therapy,and the underlying mechanisms remain to be elucidated.Molecular subtyping classifies cervical cancer based on gene expression patterns.It can further distinguish the eligible population and improve the clinical management of cervical cancer patients.Here,we summarize recent advances in translational research outcomes,the results of clinical trials of targeted therapy and immunotherapy,and the molecular subtypes of cervical cancer.
作者
范典
郑博豪
周圣涛
Dian Fan;Bohao Zheng;Shengtao Zhou(Department of Obstetrics and Gynecology,West China Second University Hospital,Sichuan University/West China Women's and Children's Hospital,Chengdu 610041,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2020年第21期1100-1107,共8页
Chinese Journal of Clinical Oncology
关键词
宫颈癌
分子分型
靶向治疗
免疫治疗
cervical cancer
molecular subtypes
targeted therapy
immunotherapy
